Amgen Agrees to $762M Fine for Drug Misbranding

The biopharmaceutical company Amgen, which is based in Thousand Oaks, Calif., has pleaded guilty to a federal misdemeanor for misbranding its anemia drug and agreed to pay $762 million in fines and penalties, according to a Washington Post report.

Advertisement

The company agreed to pay $612 million in a civil settlement, a $14 million criminal forfeiture payment and a $136 million criminal fine, according to the report.

More Articles on Pharmaceutical Settlements:

Johnson & Johnson to Pay $181M Settlement Over Risperdal Marketing
J&J to Pay $2.2B Settlement to End Risperdal Probes
Pfizer Reaches $60M Settlement Over Foreign Bribe Allegations

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Advertisement

Next Up in Legal & Regulatory Issues

Advertisement

Comments are closed.